Physician profile
Claudia E Cea
NPI 1083677892
$2,614.99
in general payments reported to CMS, 2019-2025
30 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $123 · 2022: $154 · 2023: $559 · 2024: $686 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $352.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $338.62 | 2022-2025 | Vraylar, Qulipta, Orilissa |
| Astrazeneca Pharmaceuticals LP | $336.24 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $235.52 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $147.38 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $128.28 | 2019 | |
| Pfizer INC. | $125.24 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $108.79 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $103.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.77 | 2019-2024 | Jardiance |
| Abbott Laboratories | $76.64 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $59.62 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $56.41 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $51.35 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $46.98 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.53 | 2023-2024 | Xifaxan |
| Amarin Pharma, INC. | $42.10 | 2019-2020 | |
| Mylan Specialty L.P. | $39.44 | 2023-2024 | Yupelri |
| Radius Health, INC. | $28.18 | 2019 | |
| Kyowa Kirin, INC. | $26.08 | 2024 | Crysvita |
| Astellas Pharma US INC | $24.53 | 2019 | |
| Dexcom, INC. | $23.46 | 2024 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $21.00 | 2024 | Horizant |
| Novartis Pharmaceuticals Corporation | $20.65 | 2020 | |
| Baxter Healthcare | $15.45 | 2022 | |
| Therapeuticsmd, INC. | $15.26 | 2019 | |
| Circassia INC. | $14.94 | 2019 | |
| Irhythm Technologies, INC. | $14.27 | 2023 | Zio Xt Patch |
| Arbor Pharmaceuticals, INC. | $12.07 | 2019 | |
| Allergan, INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Cea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.